BTK and B-cell chronic lymphocytic leukemia: However, ongoing studies with acalabrutinib and other novel and more specific BTK inhibitors will ultimately clarify whether the reported effects are due to ITK inhibition or normalization of the inflammatory microenvironment in ibrutinib-treated CLL patients.